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Poster Session II S299CONCLUSIONS: CLO/BU is a mid-intensity allo HSCT regi-
men with promising anti-leukemic efficacy that seems to be well tol-
erated without significant cardiac, renal or pulmonary toxicities.
CLO/BU resulted in full engraftment by day 30 in all patients. En-
rolment is closed; data collection/analysis is ongoing to determine
the practicality of this regimen being studied in a multicenter
comparative clinical trial.
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SIBLING ALLOGENEIC HSCT IN MYELOID MALIGNANCIES
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Benlloch, L.9, Sanz, G.3 1Hospital 12 de Octubre, Madrid, Spain;
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Background:There is a need to improve the conditioning regimens
for allogeneic HSCT, reducing the regimen related toxicity while
maintaining the anti-leukemic effect. The combination of myeloa-
blative doses of intravenous busulphan (BU) with fludarabine (F)
has been utilized with an improved safety profile.
Objective:We aimed to test the efficacy and safety of this combina-
tion (BUF), with a single daily dose of BU, since prior pharmacologic
and clinical studies support its safety compared with standard 4-daily
doses.
Patients: Sixty seven consecutive adult patients undergoing HLA
identical sibling allogeneicHSCT formyeloidmalignancies were re-
cruited from eight Spanish institutions. Their main characteristics
are shown in table 1.
Table 1. Patients characteristicsPATIENTS 67
Age: median (range) years 45 (17-74)
Patients aged > 55 years 30%
Male gender 58%
DISEASE
AML 35 (52.2%)
MDS Intermediate/High risk 21 (31.3%)
Secondary AML 5 (7.5%)
Myeloproliferative disorder 6 (9%)Conditioning regimen consisted in BU, one daily IV infusion (3.2
mg/kg/d) for 4 days (total dose 12.8 mg/kg), combined with F, 40
mg/m2 daily (total dose 160 mg/m2). GVHD prophylaxis consisted
in cyclosporine and methotrexate. Antimicrobial and other support-
ive measures were followed at each institution policies. Donor graft
source was PB in 76% and BM in 24% of cases. Median CD34 cells
infused were 4.0 mill/kg (0.6-17).
Results: All but one patient engrafted, with a median of 14 days (8-
34) for 0.5 granulocytes and 12 days (7-46) for 20 platelets.Main tox-
icities (Bearman) were grade 1. Major toxicity was mucositis (Grade
2 or 3, 38%of cases). There were 3 grade-2 VOD cases (4.5%) which
resolved. Acute GVHD grade 2-4 incidence was 22%. Day-100 ac-
cumulated mortality was 4.5%. The median follow-up of this ongo-
ing study is 14 months (3-51). At the time of this interim analysis, the
relapse free survival is 79.8% and overall survival 80.7%. Major
causes of death were relapse (59%) and infection or toxicity (35%).
In conclusion, in the HLA identical allogeneic HSCT setting BUF
provides excellent tumour control and low transplant related toxicity
and mortality. In particular, the incidence of VOD is\ 5%.
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IMPACT OF INJECTION VOLUME AND INFUSION RATE IN A LARGE ANI-
MAL MODEL DESIGNED TO OPTIMIZE INTRABONE TRANSPLANTATION
OF HEMATOPOIETIC STEM CELLS
Pantin, J.M.1, Robert, H.F.2, Chen,M.Y.3, Timothy, H.2, Randall, C.R.2,
Childs, R.W.1 1National Institutes of Health, Bethesda, MD; 2National
Institutes of Health, Bethesda, MD; 3National Institutes of Health,
Bethesda, MDBackground: The intrabone (IB) route of stem cell administration
results in improved engraftment in murine models of transplanta-
tion. However, human clinical trials have yet to establish that hema-
topoietic stem cell (HSC) engraftment is improved with the use of IB
delivery. The use of IB vascular access can rapidly restore systemic
blood volume and pressure in shock situations, although this access
route can be associated with pulmonary emboli. Furthermore, both
pressure and shear stress, which have not been characterized with
conventional IB delivery techniques, may damage HSCs compro-
mising their ability to engraft. Murine models do not have compar-
ative anatomy or physiology to predict the dynamics ofHSC delivery
in humans following IB injection. In contrast, swine have similar car-
diovascular physiology and size analogous to humans and can be
used as a model to study the fluid dynamics of IB injection.
Methods: Forty-five to 60 kg domestic swine were placed under
general anesthesia with IB access of the pelvis achieved using an On-
Control driver (Vidacare). Isovue was injected into the pelvis at vary-
ing volumes and rates and the entire pelvis was imaged by 320-slice
ultrafast continuous dynamicCT (Toshiba Aquilion). Pulmonary ar-
tery, carotid artery and intramarrow cavity pressures weremonitored
continuously both during and after injection into the pelvis.
Results:Wefirst characterized the comparative vascular anatomy of
the porcine pelvis. Themajor arterial blood supply to the pelvic bone
marrow was found to arise from branches of the internal iliac artery
with venous drainage occurring through the iliac vein. IB injection of
contrast led to an immediate systemic delivery into the central ve-
nous circulation. Reducing the infusion volume and slowing the
rate of the infusion both produced smaller increases in IB marrow
pressure and post-injection peak pulmonary artery systolic pressure
(PASP).
Table 1. Post IB Injection Changes in Intramarrow pressure
and Peak PASP
D Peak PulmonaryVolume
Injected (mL)Rate
Injected
(mL/s)Number of
InfusionsD Intramarrow
Pressure
(mmHg)
Mean ± S.E.Artery Systolic
Pressure
(PASP) (mmHg)
Mean ± S.E.10 0.1 4 159.3 ± 57.7 1.5 ± 0.7
10 0.2 3 300.3 ± 149.3 3.5 ± 1.0
10 0.5 2 803.4 ± 483.0 13.0 ± 5.1
10 1.0 2 1196.0 ± 265.5 8.9 ± 9.3
10 2.5 3 1689.0 ± 116.0 2.2 ± 1.0
5 0.1 2 128.7 ± 60.2 -0.5 ± 0.4
5 0.2 2 256.7 ± 42.7 1.3 ± 1.3
5 0.5 1 802.9 6.1
5 1.0 1 1490.8 0
5 2.5 1 997.5 2Conclusions: The IB route of injection provides rapid access to the
central venous circulation. Increasing IB infusion volumes and/or IB
infusion rates led to profound increases in intramarrow pressures and
significantly increases PASP. These data suggest continuous moni-
toring of IB pressures is necessary for studies aimed at characterizing
stem cell trafficking and to optimize the retention of HSC in the
intrabone marrow space following IB injection.402
VARICELLA ZOSTER REACTIVATION AFTER CORD BLOOD TRANSPLANTA-
TION: COMPARISON WITH UNRELATED BONE MARROW TRANSPLANTA-
TION
Asano-Mori, Y.1, Nishida, A.1, Ikebe, T.1, Ishiwata, K.1, Nakano, N.1,
Tsuji, M.1, Yamamoto, H.1, Izutsu, K.1, Uchida, N.1, Masuoka, K.2,
Wake, A.1, Yoneyama, A.3, Makino, S.4, Taniguchi, S.1 1Toranomon
Hospital, Tokyo, Japan; 2Mishuku Hospital, Tokyo, Japan; 3Toranomon
Hospital, Tokyo, Japan; 4Toranomon Hospital, Tokyo, Japan
Varicella zoster virus (VZV) infection remains an important prob-
lem after allogeneic hematopoietic stem cell transplantation, because
VZV-related complications including post-herpetic neuralgia
